

~~CONFIDENTIAL~~

the formula:



10

$n$  is an integer between 2 and 20,

15

20



$\text{Cat}^+$  is an organic or inorganic cation,

for the use thereof as therapeutically active substances.

30



Cat<sup>+</sup> is an organic or inorganic cation,

$n$  is an integer between 2 and 20.

5




20

25



35



- and substituents for which there is a compound R<sup>2</sup>-O-PPP, where PPP denotes the triphosphate group.

sub a<sup>1</sup>

5 6) Compounds as claimed in one of claims 1, 3 and 5, comprising at least one group selected from among the group comprising nucleoside derivatives, oligonucleotides, nucleic acids (RNA, DNA), amino acids, peptides, proteins, monosaccharides, oligosaccharides, polysaccharides, fatty acids, simple lipids, complex lipids, folic acid, tetrahydrofolic acid, phosphoric acids, inositol, vitamins, co-enzymes, flavonoids, aldehydes, halohydrins and epoxides.

10 7) Compounds as claimed in claims 5 and 6, in which R<sup>2</sup> is moreover selected from among the group comprising nucleoside derivatives, oligonucleotides, nucleic acids (RNA, DNA), amino acids, peptides, proteins, monosaccharides, oligosaccharides, polysaccharides, fatty acids, simple lipids, complex lipids, folic acid, tetrahydrofolic acid, phosphoric acids, inositol, vitamins, co-enzymes, 15 flavonoids, aldehydes, halohydrins, phosphoepoxides of the formula (1) and epoxides.

8) Novel phosphoepoxide compounds of the formula:



(21)

where R<sup>1</sup> is selected from among —CH<sub>3</sub> and —CH<sub>2</sub>—CH<sub>3</sub>,

n is an integer between 2 and 20.

sub a<sup>2</sup>

9) Compounds as claimed in one of claims 3 to 5, 7 or 8 for the use thereof as therapeutically active substances.

25 10) Compounds as claimed in one of claims 1 to 9 for the use thereof as Ty982 lymphocyte activators.

11) Compounds as claimed in one of claims 1 to 10 for the use thereof as Ty982 lymphocyte antigens in a therapeutic composition, in particular an immunostimulant therapeutic composition or a vaccine, for primates.

5



an intermediate compound comprising

15



- the intermediate compound is reacted with a hydroxide order to convert the halohydrin functions of the intermediate e functions.

25



35

~~15) Composition for extracorporeal diagnostics, wherein it comprises at least one compound as claimed in one of claims 3 to 5, 7 or 8.~~

16) Therapeutic composition, wherein it comprises at least one compound as claimed in one of claims 1 to 8.

17) A therapeutic composition, wherein it comprises a quantity capable of being administered to a primate, in particular in contact with the peripheral  
5 bloodstream or topically, of at least one compound as claimed in one of claims 1 to 8.

18) The composition as claimed in one of claims 15 to 17, wherein it moreover comprises primate  $T\gamma\delta 2$  lymphocytes.

19) The composition as claimed in one of claims 15 to 18, wherein it moreover comprises a proportion of interleukin suitable to bring about  
10 lymphocyte growth in the medium into which it is to be administered.

20) A process for the production of a composition having the characteristic of activating  $T\gamma\delta 2$  lymphocytes, in which at least one compound as claimed in one of claims 1 to 8 is used.

21) A process for the production of a therapeutic composition  
15 intended for the preventive or curative treatment of a pathological condition which produces cells sensitive to  $T\gamma\delta 2$  lymphocytes, in which process at least one compound as claimed in one of claims 1 to 8 is used.

22) A process for the production of a therapeutic composition intended to be administered to a primate for the preventive or curative treatment of a  
20 pathological condition which produces cells sensitive to  $T\gamma\delta 2$  lymphocytes, in which process at least one compound as claimed in one of claims 1 to 8 is used.

23) A process for the production of a therapeutic composition intended to be administered to a primate for the preventive or curative treatment of a pathological condition selected from among the group comprising cancers, infectious  
25 diseases, parasitic conditions, and pathological immunodeficiency syndromes, in which process at least one compound as claimed in one of claims 1 to 8 is used.

24) The process according to claim one of claims 20 to 23, in which at least one compound as claimed in one of claims 1 to 11 is brought into contact with a medium which contains  $T\gamma\delta 2$  lymphocytes, and is compatible with T  
30 lymphocyte growth, in a quantity suitable for activating these  $T\gamma\delta 2$  lymphocytes in this medium.

25) The process as claimed in claim 24, in which said medium comprises a substance selected from among primate blood and primate blood extracts.

26) An extracorporeal  $T\gamma 26\delta 9$  lymphocyte activation process, in which the  $T\gamma 9\delta 2$  lymphocytes are brought into contact with at least one compound as claimed in one of claims 1 to 8 in an extracorporeal medium which contains  $T\gamma 9\delta 2$  lymphocytes and is compatible with T lymphocyte growth.

27) The process as claimed in claim 26, in which at least one compound as claimed in one of claims 1 to 8 is used at a concentration in the medium which brings about activation of polyclonal proliferation of  $T\gamma 9\delta 2$  lymphocytes.

28) The process as claimed in one of claims 26 to 27, in which a proportion of interleukin suitable to bring about lymphocyte growth in the medium is introduced into the medium.

09705065-030404  
T07020-55090260